| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/20/2005 | EP1523311A1 Calcium lactate and whey permeate for lowering the triglyceride level |
| 04/20/2005 | EP1523310A2 Method to inhibit ischemia and reperfusion injury |
| 04/20/2005 | EP1523309A2 Nmda receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau |
| 04/20/2005 | EP1523307A1 Use of neurotoxic substances for the production of a means for the treatment of joint pain and method for application of said means |
| 04/20/2005 | EP1523306A1 Use of modulators of the signal transduction path using the protein kinase fyn for the treatment of tumorous diseases |
| 04/20/2005 | EP1523305A2 Device and patch for controlling the release of vanillin |
| 04/20/2005 | EP1523303A1 Medicaments containing vardenafil hydrochloride trihydrate |
| 04/20/2005 | EP1523302A2 Method for producing crystals from active ingredients in medicaments, crystals obtained therefrom and the use thereof in pharmaceutical formulations |
| 04/20/2005 | EP1523239A1 Use of a composition and a cleaning tablet containing said composition for disinfecting purposes |
| 04/20/2005 | EP1458355A4 Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol |
| 04/20/2005 | EP1448547B1 Pyridine derivatives as nmda receptor ligands |
| 04/20/2005 | EP1443934B1 Benzotriazepines as gastrin and cholecystokinin receptor ligands |
| 04/20/2005 | EP1443921B1 Production of pure stereoisomers of tricyclo-[5.2.1.0(2.6)]-dec-9-yl-xanthate esters and their use as medicaments |
| 04/20/2005 | EP1435961A4 Treatment for lupus erythematosus |
| 04/20/2005 | EP1435940A4 Treatment of scleroderma |
| 04/20/2005 | EP1401456A4 Method fron determining the efficacy of reverse cholesterol transport enhancing agents |
| 04/20/2005 | EP1392316B1 Benzo[d]azepine derivatives as 5-ht6 receptor antagonists. |
| 04/20/2005 | EP1383494A4 Compositions and methods for the prevention and treatment of human prostate cancer |
| 04/20/2005 | EP1373249B1 Imidazolidine derivatives, their preparation, and their use as antiinflamatory agent |
| 04/20/2005 | EP1365737B1 Stable salts of o-acetylsalicyclic with basic amino acids |
| 04/20/2005 | EP1363626A4 Antifungal remedy formulation for external application |
| 04/20/2005 | EP1349847B1 Oxybenzamides derivatives as factor xa inhibitors |
| 04/20/2005 | EP1349843B1 Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors |
| 04/20/2005 | EP1317306B1 Transdermal electrotransport device and method for manufacturing same |
| 04/20/2005 | EP1315807B1 Chimeric antisense oligonucleotides of arabinofuranose analogues and deoxyribose nucleotides |
| 04/20/2005 | EP1307425B1 Novel n-(2-phenyl-3-aminopropyl)naphtamides |
| 04/20/2005 | EP1307263B1 New use of lipase inhibitors |
| 04/20/2005 | EP1283839B1 Adenosine a2a receptor antagonists |
| 04/20/2005 | EP1254133B1 Indol-3-yl derivatives and their use as integrin inhibitors |
| 04/20/2005 | EP1252158B1 Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes |
| 04/20/2005 | EP1226110B1 Bicyclic amino acids as pharmaceutical agents |
| 04/20/2005 | EP1196417B1 1,2,3,4,5,6-HEXAHYDROAZEPINO 4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION |
| 04/20/2005 | EP1191935B1 Treatment or prevention of coronary graft vasospasm |
| 04/20/2005 | EP1189926B1 Rapid dehydration of proteins |
| 04/20/2005 | EP1178810B1 Use of bisphosphonic acids for treating angiogenesis |
| 04/20/2005 | EP1177185B1 4, 5, 6, 7-tetrahydroindazole derivatives as antitumor agents |
| 04/20/2005 | EP1165495B1 Resorcinol derivatives |
| 04/20/2005 | EP1152751B1 Desoxypeganine transdermal therapeutic system |
| 04/20/2005 | EP1144395B1 2-amino-benzoxazinone derivatives for the treatment of obesity |
| 04/20/2005 | EP1143977B1 2-oxy-benzoxazinone derivatives for the treatment of obesity |
| 04/20/2005 | EP1141326B1 Human akt-3 |
| 04/20/2005 | EP1140904B1 Farnesyl protein transferase inhibitors |
| 04/20/2005 | EP1135168B1 Peptides carrying substances across the blood brain barrier |
| 04/20/2005 | EP1135117B1 Medikament for treating chronic obstructive pulmonary disease |
| 04/20/2005 | EP1129077B1 Fluorinated 3,4-dihydroquinoline derivatives used as nos inhibitors |
| 04/20/2005 | EP1089968B1 Thyroid hormone analogues and methods for their preparation |
| 04/20/2005 | EP1082093B8 Anti-germ attachment - composition |
| 04/20/2005 | EP1076651B1 Substituted sulphonyl cyanamides, method for producing same and their use as medicament |
| 04/20/2005 | EP1059911B1 Formulations with an anti-viral effect |
| 04/20/2005 | EP1042287B1 Indole derivatives as inhibitors of factor xa |
| 04/20/2005 | EP1029851B1 Piperazine compounds and medicinal use thereof |
| 04/20/2005 | EP1015431B1 2-aminopyridines as inhibitors of cyclooxygenase-2 |
| 04/20/2005 | EP1009753B1 Hypoxia-regulated genes |
| 04/20/2005 | EP1001685B1 Nutritional compositions containing methionine |
| 04/20/2005 | EP0984947B1 Oxazolidinone antibacterial agents having a thiocarbonyl functionality |
| 04/20/2005 | EP0957925B1 Treatment of osteoarthritis by administering poly-n-acetyl-d-glucosamine |
| 04/20/2005 | EP0954278B1 Pharmaceutical compositions containing kukui nut oil |
| 04/20/2005 | EP0949919B1 A process for stabilizing levogyre ascorbic acid (laa) and stable laa compositions |
| 04/20/2005 | EP0880514B1 Non-steroidal polycyclic ring sulphamate derivatives, their preparation and their use as oestrone sulphatase inhibitors |
| 04/20/2005 | EP0775213B1 Adenovirus comprising a gene coding for glutathion peroxidase |
| 04/20/2005 | EP0766669B1 Tri-substituted phenyl derivatives useful as pde iv inhibitors |
| 04/20/2005 | EP0721455B9 Tetrahydropyridine-(or 4-hydroxypiperidine)alkylazoles having an affinity for sigma and/or 5ht1a receptors |
| 04/20/2005 | CN1608133A Use of a double-stranded ribonucleic acid for treating an infection with a positivestrand rna-virus |
| 04/20/2005 | CN1608127A Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid A(3D-MLA) |
| 04/20/2005 | CN1608073A A process for preparing N-acylated lysophosphatidylcholine compounds and a pharmaceutical composition for treatment of metabolic bone disease comprising said compounds |
| 04/20/2005 | CN1608069A Selective androgen receptor modulators and methods for their identification, design and use |
| 04/20/2005 | CN1608068A Bridged bicyclic amino acid-derived [1, 4]benzodiazepine vasopressin receptor antagonists |
| 04/20/2005 | CN1608067A Pyrrolopyrimidines as phosphodiesterase vii inhibitors |
| 04/20/2005 | CN1608065A Phenyl substituted triazoles and their use as selective inhibors of akl5 kinase and pharmaceutical compositions containing the compounds |
| 04/20/2005 | CN1608064A Novel compounds |
| 04/20/2005 | CN1608063A Indolinone derivatives |
| 04/20/2005 | CN1608062A Salt forms of e-2-methoxy-n-(3-{4-[3 methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production |
| 04/20/2005 | CN1608061A Therapeutic isoquinoline compounds |
| 04/20/2005 | CN1608060A Diaryl 1, 2, 4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 04/20/2005 | CN1608059A Bipyridyl derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 04/20/2005 | CN1608057A Method for the preparation of citalopram |
| 04/20/2005 | CN1608056A Carboxylic acid derivative compounds and agents comprising the compounds as active ingredient |
| 04/20/2005 | CN1608055A Compounds for the treatment of metabolic disorders |
| 04/20/2005 | CN1608054A Therapeutic quinolone compounds with 5-HT-antagonistic properties |
| 04/20/2005 | CN1608053A Heterocyclic derivatives of glycinamide and its pharmaceutical uses |
| 04/20/2005 | CN1608051A Method of resolving amlodipine racemate |
| 04/20/2005 | CN1608050A Piperazine derivative |
| 04/20/2005 | CN1607962A Manufacture of polyglutamate-therapeutic agent conjugates |
| 04/20/2005 | CN1607955A Methods and compositions for control of coccidiosis |
| 04/20/2005 | CN1607954A Pregnane steroids for use in the treatment of cns dysfunction |
| 04/20/2005 | CN1607953A Non-nucleosidic inhibitors of reverse transcriptase as antagonists of cell proliferation and inducers of cell differentiation |
| 04/20/2005 | CN1607952A Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor |
| 04/20/2005 | CN1607951A Quinoline derivatives as neuropeptide y antagonists |
| 04/20/2005 | CN1607950A A liquid pharmaceutical formulation comprising nicotine for the administration to the oral cavity |
| 04/20/2005 | CN1607949A Peptide arginals and methods for treating disseminated intravascular coagulation |
| 04/20/2005 | CN1607948A Composition comprising paracetamol and a bitterness masking component |
| 04/20/2005 | CN1607947A Delayed release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol |
| 04/20/2005 | CN1607946A Dermatological/cosmetic gels comprising at least one retinoid and benzoyl peroxide |
| 04/20/2005 | CN1607945A Composite dosage forms with a coating portion |
| 04/20/2005 | CN1607944A Pre-formulation for the tabletting of natural mixtures of conjugated estrogens |
| 04/20/2005 | CN1607943A Matrix film tablet with controlled release of a natural mixture of conjugated estrogens |
| 04/20/2005 | CN1607942A Pharmaceutical compositions in particulate form |
| 04/20/2005 | CN1607941A Pharmaceutical compositions in particulate form |
| 04/20/2005 | CN1607940A Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
| 04/20/2005 | CN1607938A Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol |